TEGOBUVIR ..IN PHASE II FOR HEPATITIS C

New Drug Approvals

TEGOBUVIR

A non-structural protein 5B polymerase inhibitor
for Treatment of chronic hepatitis C

5-[6-[2,4-Bis(trifluoromethyl)phenyl]pyridazin-3-ylmethyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine

CHEMICAL NAMES

1. 5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-
2-(2-fluorophenyl)-

2. 5-({6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)-2-(2-fluorophenyl)-5H-
imidazo[4,5-c]pyridine

MOLECULAR FORMULA C25H14F7N5

MOLECULAR WEIGHT 517.4

MANUFACTURER Gilead Sciences, Inc.

CODE DESIGNATION

  • GS 333126
  • GS 9190
  • GS-333126
  • GS-9190
  • Tegobuvir
  • UNII-5NOK5X389M

CAS REGISTRY NUMBER 1000787-75-6

GS-9190, an RNA-directed RNA polymerase (NS5B) inhibitor, is in phase II clinical evaluation at Gilead for the treatment of hepatitis C virus (HCV) infection. A clinical trial with GS-9190 in combination with peginterferon alfa-2a and ribavirin and with GS-9451 or with GS-9256 in treatment-naive subjects with chronic genotype 1 HCV infection was discontinued due to serious adverse events.

Gilead (Originator)
Katholieke Universiteit Leuven (Originator)

……………………………………….

tegobuvir

PATENTS

WO 2005063744

WO 2008005519

WO 2009009001

WO 2010151488

WO 2010151487

WO 2010151472

WO 2011072370

WO 2011156757

WO 2012087596

WO 2013101550

View original post 2,055 more words

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s